What are the difficulties with dasatinib in terms of medical insurance reimbursement?

Dasatinib (Dasatinib) is an important drug in the fight against chronic myelogenous leukemia (CML) and specific acute lymphoblastic leukemia (ALL). It has good efficacy. Chronic myeloid leukemia has developed into a chronic disease that can be controlled with tyrosine kinase inhibitor therapy. Now that long-term survival has been achieved in patients with chronic myelogenous leukemia, the focus of treatment has shifted toward dose optimization, with the goal of maintaining response while improving quality of life. Although it has been included in the national Class B medical insurance drug list in China, in practice, many patients find that their expenses cannot be reimbursed as expected. What is the reason?

Medical insurance reimbursement policies are not uniform across regions. In areas with abundant medical insurance resources and strong economic strength, the reimbursement of dasatinib may be relatively smooth; in places with limited medical insurance resources or poor economic conditions, reimbursement becomes difficult due to its high price tag. Even in the same region, different medical insurance types, reimbursement ratios and limits may affect the reimbursement of dasatinib.

Furthermore, medical insurance reimbursement is not static and is subject to various conditions. In addition to the type and severity of the disease suffered by the patient, factors such as the choice of treatment plan and the necessity of drug use will also affect the reimbursement results. For example, in some cases, the medical insurance department may consider reimbursing dasatinib only if it is clearly labeled as the first choice or only effective treatment. In addition, personal financial status is also a factor that cannot be ignored. For those patients with better financial conditions who can afford part or all of the drug costs, they may have an easier time obtaining reimbursement from medical insurance; conversely, patients with poorer financial conditions may face greater obstacles to reimbursement.